EACR AACR SIC. from Cancer Biology to the Clinic. Advance Programme & Call for Abstracts ITALY JUNE. Anticancer Drug Action and Drug Resistance:

Transcription

1 Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic Organised by: Advance Programme & Call for Abstracts

2 -- ORGANIZING COMMITTEE n Richard Marais (UK) - Conference Co-Chair n Pasi Jänne (US) - Conference Co-Chair n Riccardo Dolcetti (IT) - Conference Co-Chair n Paola Chiarugi (IT) n Silvia Giordano (IT) n Moshe Oren (IL) n Daniel Peeper (NL) n Neil Shah (US) n Alice Shaw (US) n Robert Kenney (UK) n Jeffrey M. Ruben (US) EXECUTIVE SCIENTIFIC COMMITTEE n Richard Marais (UK) - Conference Co-Chair n Pasi Jänne (US) - Conference Co-Chair n Riccardo Dolcetti (IT) - Conference Co-Chair n Paola Chiarugi (IT) n Silvia Giordano (IT) n Moshe Oren (IL) n Daniel Peeper (NL) n Neil Shah (US) n Alice Shaw (US) SAVE THE DATES Abstract submission opens 3 NOVEMBER 2014 Early Rate Registration Opens 3 NOVEMBER 2014 Abstract Submission Closes 6 FEBRUARY Early Rate Registration Closes 23 FEBRUARY Regular Rate Registration Closes 21 MAY Late Rate Registration Opens AS OF 22 MAY Conference Venue & Secretariat Secretariat ECCO-the European CanCer Organisation Avenue E. Mounier 83 B-1200 Brussels Belgium Tel: +32 (0) Fax: +32 (0) eas@ecco-org.eu Venue Firenze Fiera Piazza Adua Florence, Italy Tel: Fax: Accreditation for Continuing Medical Education (CME) Continuing Medical Educational Activity AMA PRA Category 1 available. Italian Continuing Medical Education (CME) credits available. 2 EAS ADVANCE PROGRAMME

3 Letter of Welcome Dear Colleagues, It is our pleasure to invite you to participate in a new and very special conference: Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic. The conference will take place June in Florence, Italy., and (Italian Cancer Society) have joined forces to organise a strong multidisciplinary meeting of cancer researchers and practising clinical experts as well as those focused on the development of new targeted therapeutics. Inhibitors targeting mutant proteins have shown unprecedented impact on the rate and duration of clinical responses. Despite these results, most cancers treated with single agents rapidly acquire resistance through a variety of mechanisms, severely limiting clinical benefit. This conference will have presentations ranging across the identification of novel drug targets; non-oncogene addiction and synthetic lethality; discovery of drug resistance mechanisms; the development of combinatorial therapies; and related translational topics, across a wide spectrum of cancer types. We invite you to take an active part in this ground-breaking conference and contribute your own invaluable expertise and unique perspective to its work. Richard Marais, Pasi Jänne, Riccardo Dolcetti, Conference Co-Chair () Conference Co-Chair () Conference Co-Chair () EAS ADVANCE PROGRAMME 3

4 Advance Programme at a Glance SATURDAY, 20 SUNDAY, 21 Auditorium Auditorium Sala Verde Meet the Expert Alice Shaw (US) Meet the Expert Pasi Jänne (US) Keynote Lecture New Drugs Jose Baselga (US) Proffered Papers to be announced Poster Viewing / Coffee Break Opening Address Opening Lecture Non-coding RNA Frank J. Slack (US) Coffee Break Plenary Symposium Immunotherapy James P. Allison (US) Suzanne Topalian (US) 2 Presenters from best s Ton Schumacher (NL) Exhibition Symposium Melanoma Targeted Drugs Richard Marais (UK) Daniel Peeper (NL) 2 Presenters from best s Caroline Robert (FR) Lunch Poster Defence Symposium Tumour Heterogeneity Elaine Mardis (US) Neil Shah (US) 2 Presenters from best s Anton Berns (NL) Poster Viewing / Coffee Break Symposium Circulating Tumour Cells Federica Di Nicolantonio (IT) Caroline Dive (UK) 2 Presenters from best s Satellite Symposium* Exhibition Welcome Reception :00 Keynote Lecture Cancer Genomics and Drug Resistance Levi A. Garraway (US) For the most up-to-date version, visit * is not providing CME credit for Satellite Symposia 4 EAS ADVANCE PROGRAMME

5 MONDAY, 22 TUESDAY, 23 Auditorium Sala Verde Auditorium Meet the Expert Alberto Bardelli (IT) Meet the Expert Silvia Giordano (IT) Keynote Lecture Precision Medicine in Oncology Pasi Jänne (US) Keynote Lecture Angiogenesis Peter Carmeliet (BE) Keynote Lecture Epigenetics Manel Esteller (ES) Proffered Papers to be announced Coffee Break Poster Viewing / Coffee Break Symposium Microenvironment Laurence Zitvogel (FR) Ravid Strausmann (IL) 2 Presenters from best s Mario Colombo (IT) Lunch Poster Defence Symposium Metabolism Matthew Vander Heiden (US) Paola Chiarugi (IT) 2 Presenters from best s Karen Vousden (UK) Satellite Symposium* Exhibition Symposium Inflammation Paola Allavena (IT) Lisa M. Coussens (US) 2 Presenters from best s Thomas Tüting (DE) Coffee Break :45 Closing Remarks Pezcoller-Prodi Lecture Awards / Highlights Poster Viewing / Coffee Break Symposium Undruggable Targets speaker to be confirmed Gerard Evan (UK) 2 Presenters from best s :00 Keynote Lecture Animal Models Mariano Barbacid (ES) 20:00 Conference Dinner / Networking EAS ADVANCE PROGRAMME 5

6 Detailed Advance Programme SATURDAY 20 SUNDAY 21 Opening Address 14:00-14:30 Welcome message by Chair: R. Marais (United Kingdom) Welcome Message by Chair: P. Jänne (USA) Welcome message by Chair: R. Dolcetti (Italy) Meet the Expert 07:30-08:30 07:30 Speaker: A.T. Shaw (USA) Meet the Expert 07:30-08:30 Opening Lecture: Non-coding RNA 14:30-15:30 Chair: P. Jänne (USA) 14:30 MicroRNA-based therapeutics in cancer Speaker: F.J. Slack (USA) Plenary Symposium: Immunotherapy 16:00-18:00 Chair: R. Dolcetti (IT) 16:00 Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for a cure Speaker: J.P. Allison (USA) 16:30 PD-1 pathway blockade: future clinical directions Speaker: S.L. Topalian (USA) 17:00 Presenter to be selected from best 17:10 Presenter to be selected from best 17:20 What T cells see on human cancer Speaker: T. Schumacher (Netherlands) 17:50 Discussion & Roundup 18:00 Welcome Reception 07:30 Speaker: P. Jänne (USA) Keynote Lecture: New Drugs 08:30-09:15 Chair: S. Giordano (IT) 08:30 New drugs Speaker: J. Baselga (USA) Proffered Papers: 09:15-10:15 Details to be announced in Symposium: Melanoma Targeted Drugs 10:45-12:30 Chair: A. Berns (Netherlands) 10:45 Improving patient outcomes to targeted therapies in melanoma Speaker: R. Marais (United Kingdom) 11:10 Function-based genomic approaches for melanoma drug target discovery Speaker: D. Peeper (Netherlands) 11:35 Presenter to be selected from best 11:45 Presenter to be selected from best 11:55 Melanoma resistance to targeted therapy: A translation issue? Speaker: C. Robert (France) 12:20 Discussion & Roundup 6 EAS ADVANCE PROGRAMME

7 Symposium: Tumour Heterogeneity 14:30-16:15 Chair: C. Dive (United Kingdom) 14:30 Genomic characterization of tumour heterogeneity during progression Speaker: E.R. Mardis (USA) 14:55 Title to be announced Speaker: N.P. Shah (USA) 15:20 Presenter to be selected from best 15:30 Presenter to be selected from best 15:40 Tumour cell heterogeneity and cell-oforigin of small cell and non-small-cell mouse lung cancer Speaker: A. Berns (Netherlands) 16:05 Discussion & Roundup Symposium: Circulating Tumour Cells 16:45-18:15 Chair: A. Bardelli (Italy) 16:45 Cancer biomarkers in circulating tumour DNA Speaker: F. Di Nicolantonio (Italy) 17:15 Versatility of circulating tumour cells in lung cancer: Biology, drug development and biomarkers Speaker: C. Dive (United Kingdom) 17:45 Presenter to be selected from best 17:55 Presenter to be selected from best 18:05 Discussion & Roundup Keynote Lecture: Cancer Genomics and Drug Resistance 18:15-19:00 Chair: R. Marais (United Kingdom) 18:15 Cancer genomics and drug resistance Speaker: L.A. Garraway (USA) MONDAY 22 Meet the Expert 07:30-08:30 07:30 Precision oncology for colorectal cancers Speaker: A. Bardelli (Italy) Meet the Expert 07:30-08:30 07:30 Applications of patient-derived xenograft models to translational cancer research Speaker: S. Giordano (Italy) Keynote Lecture: Angiogenesis 08:30-09:15 Chair: A. Shaw (USA) 08:30 Angiogenesis revisited: role and therapeutic potential of targeting endothelial metabolism Speaker: P. Carmeliet (Belgium) Proffered Papers: 09:15-10:15 Details to be announced in Symposium: Microenvironment 10:45-12:30 Chair: M. Vander Heiden (USA) 10:45 Microbiota and tumour microenvironment Speaker: L. Zitvogel (France) 11:10 Human microbiome-mediated chemoresistance Speaker: R. Straussman (Israel) 11:35 Presenter to be selected from best 11:45 Presenter to be selected from best 11:55 Extracellular matrix impinges on immune functions and shapes the tumour microenvironment Speaker: M.P. Colombo (Italy) 12:20 Discussion & Roundup EAS ADVANCE PROGRAMME 7

8 Symposium: Metabolism 14:30-16:15 Chair: to be announced 14:30 Regulation of metabolism in tumours Speaker: M. Vander Heiden (USA) 14:55 Reciprocal metabolic deregulation of tumour/stroma interplay: a new druggable synergy Speaker: P. Chiarugi (Italy) 15:20 Presenter to be selected from best 15:30 Presenter to be selected from best 15:40 Metabolic pathways and cancer treatment looking for new targets Speaker: K. Vousden (United Kingdom) 16:05 Discussion and Roundup Symposium: Undruggable Targets 16:45-18:15 Chair: K. Vousden (United Kingdom) 16:45 Title to be announced Speaker: to be announced 17:15 Targeting cancer s engines, not its drivers Speaker: G.I. Evan (United Kingdom) 17:45 Presenter to be selected from best 17:55 Presenter to be selected from best 18:05 Discussion and Roundup Keynote Lecture: Animal Models 18:15-19:00 Chair: M. Oren (Israel) 18:15 Modeling human cancer in mice: An essential tool for the development of future therapies Speaker: M. Barbacid (Spain) TUESDAY 23 Keynote Lecture: Precision Medicine in Oncology 08:30-09:15 Chair: S. Giordano (Italy) Precision medicine in oncology Speaker: P. Jänne (USA) Keynote Lecture: Epigenetics 09:15-10:00 Chair: D. Peeper (Netherlands) 09:15 Cancer pharmacoepigenetics: Genes and drugs Speaker: M. Esteller (Spain) Symposium: Inflammation 10:30-12:15 Chair: L.M. Coussens (USA) 10:30 Targeting of tumour-associated macrophages and cancer-related inflammation Speaker: P. Allavena (Italy) 10:55 Immune cells as therapeutic targets in solid tumors Speaker: L.M. Coussens (USA) 11:20 Presenter to be selected from best 11:30 Presenter to be selected from best 11:40 Neutrophilic inflammation and melanoma metastasis Speaker: T. Tüting (Germany) 12:05 Discussion & Roundup Closing Session 12:45-13:45 Chair: S. Giordano (IT) Pezcoller-Prodi Award Lecture (to be announced in ) Awards / Conference Highlights 8 EAS ADVANCE PROGRAMME

9 Call for Abstracts Abstract submission opens 3 NOVEMBER 2014 Abstract submission closes 6 FEBRUARY n Abstracts can only be submitted online. n Abstracts submitted on paper or by attachment will not be considered. n A link to submit your will be published when submission is open. For questions regarding the online submission process, contact: eas@ecco-org.eu ABSTRACT TOPICS 1. CELL AND TUMOUR BIOLOGY 6. EXPERIMENTAL / MOLECULAR THERAPEUTICS, n Cell Proliferation/Cell Cycle PHARMACOGENOMICS n Cell Death / Autophagy n Drug Discovery / Drug Design n Oncogenes and Tumour Suppressor Genes n Novel Targets, Delivery Systems n Tumour Progression: Invasion and Metastasis n Mechanisms of Drug Action, Drug Profiling n Metastases and EMT n Drug Resistance n Tumour Microenvironment n Novel Approaaches to Diagnosis of Cancer n Tumour Angiogenesis n New Therapies n Tumour Immunology AND Inflammation n Companion Diagnostics n Aging and Cancer n Personalized Medicine n Senescence 7. TUMOUR IMMUNOLOGY n Cancer Cell Metabolism n Cancer Initiating Cells / Cancer Stem Cells n Tumour Immunology n Tumour heterogeneity n Immune Suppression and Escape n Tumor Antigens and Immune Effectors 2. CANCER GENOMICS, EPIGENETICS and GENOMIC n Immunotherapy and Cancer Vaccines INSTABILITY 8. RADIOBIOLOGY / RADIATION ONCOLOGY n Genomic Alterations in Cancer n Functional Genomics n Tumour Cell Sensitization to Radiotherapy n Epigenetic Mechanisms and RNA n Radiation-activated Signaling Pathways n Genetic Instability n Cell Cycle and Apoptosis in Radiation Responses n Deep Sequencing n Radiation Oncology; Preclinical and Clinical n Translational Radiation Research 3. SIGNALING PATHWAYS 9. MOLECULAR AND GENETIC EPIDEMIOLOGY n Receptors and Signal Transduction n Gene Expression, Transcriptional Regulation n Risk Factors n Systems Biology n Biomarkers n Computational Models of Biological Systems n Risk Assessment n Omics technologies n Susceptibility Genes n Genotype / Phenotype Correlations 4. CARCINOGENESIS n Genetic Polymorphisms and Cancer Susceptibility n Mutagenesis, Carcinogen Metabolism n Epidemiology n Promotion and Progression 10. PREVENTION and EARLY DETECTION n DNA Damage and Repair n Viral Oncogenesis n Preclinical Prevention Studies, Biomarkers and Prevention n Clinical Prevention Studies 5. TRANSLATIONAL RESEARCH n Cancer Vaccines n Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment 11. OTHER n Molecular Pathology n Biomarkers with Clinical Relevance, Imaging n Prognostic Biomarkers of Therapy Response n Prognostic Value of Oncogenomics n Clinical Phase I/II Trials with Targeted Drugs and Novel Agents n Bioinformatics in Therapies and Clinical Trials n Animal Models of Cancer n Infrastructures (Biobanks, Databases, Genomic Resources, Others) To review the detailed Abstract Policies and Regulations please visit: EAS ADVANCE PROGRAMME 9

10 General Information REGISTRATION To register, go to Registration opens on 3 November REGISTRATION RATES EARLY RATE DEADLINE: 23 FEBRUARY Early Rate / / Member EUR 450 Early Rate Non Member EUR 550 Early Rate Student EUR 280 Industry Early Rate EUR 750 REGULAR RATE DEADLINE: 21 MAY Regular Rate / / Member EUR 650 Regular Rate Non Member EUR 750 Regular Rate Student EUR 330 Industry Regular Rate EUR 950 LATE RATE AS OF 22 MAY Late Rate / / Member EUR 780 Late Rate Non Member EUR 880 Late Rate Student EUR 380 Industry Late Rate EUR Day rate (only available onsite) EUR 325 All rates include local VAT ACCOMMODATION The -- Conference offers special reduced rates on accommodation in many hotels in Florence. You will receive a weblink and code when registering for the Conference so you may book online and benefit from the special rates 10 EAS ADVANCE PROGRAMME

11 EXHIBITION The -- Exhibition is an essential part of the conference and provides an opportunity to network and review important innovations. For details of all exhibition & sponsorship opportunities, download the Invitation to Industry brochure at: To discuss your specific interests, please contact Bruno De Man, Tel.: +32 (0) INSURANCE The organisers do not accept liability for individual medical, travel or personal insurance. Participants are strongly advised to make their own arrangements regarding health and travel insurance. LANGUAGE AND TRANSLATION The official language of the Conference will be English. Simultaneous translation will not be provided. CATERING Complimentary lunch and coffee will be offered to Conference delegates at the times stipulated in the Programme. OFFICIAL CARRIER Delegates to the -- Conference will be eligible for special discounts when making their flight arrangements. Details will be announced on the Conference website. PASSPORT AND VISA A valid passport and/or identity card is required for entry into Florence, Italy. A visa may be required for some countries. For specific information, please contact your local Italian Embassy at least 3 months prior to your departure to join us in Florence. EAS ADVANCE PROGRAMME 11

12 Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic Conference Secretariat: ECCO the European CanCer Organisation Avenue E. Mounier 83 B-1200 Brussels Belgium Tel.: +32 (0) Fax: +32 (0) Organised by: